Table 3.

Geometric mean (95% CI) of blood arsenic (μg/L) and the percent change in blood arsenic from week 12 to week 24 by second phase treatment group.

Time or time comparison	Statistic	Placebo	FA400 (μg) continued	FA400 (μg) switched to placebo	FA800 (μg) continued	FA800 (μg) switched to placebo
Week 12	Mean (95% CI)	7.62 (6.72, 8.64) (n = 101)	8.56 (7.33, 10.00) (n = 77)	8.25 (7.09, 9.60) (n = 76)	7.39 (6.56, 8.33) (n = 77)	6.97 (6.05, 8.04) (n = 73)
Week 13	Mean (95% CI)	7.37 (6.50, 8.35) (n = 102)	8.22 (6.93, 9.76) (n = 77)	8.28 (6.99, 9.82) (n = 75)	7.04 (6.21, 7.99) (n = 77)	6.65 (5.73, 7.72) (n = 73)
Week 18	Mean (95% CI)	7.89 (6.96, 8.95) (n = 102)	8.01 (6.77, 9.48) (n = 77)	8.27 (7.06, 9.69) (n = 75)	6.91 (5.90, 8.10) (n = 74)	7.04 (6.07, 8.15) (n = 74)
Week 24	Mean (95% CI)	8.12 (7.23, 9.13) (n = 102)	8.52 (7.30, 9.95) (n = 77)	8.15 (7.02, 9.46) (n = 74)	7.69 (6.60, 8.96) (n = 76)	7.62 (6.66, 8.73) (n = 74)
Week 13 vs. Week 12	Percent change (95% CI)a	–2.4 (–6.7, 2.0) (n = 101)	–4.0 (–8.8, 1.1) (n = 77)	0.1 (–5.3, 5.7) (n = 75)	–4.7 (–9.1, –0.1) (n = 77)	–5.0 (–9.6, –0.1) (n = 72)
Week 18 vs. Week 12	Percent change (95% CI)	4.3 (–2.9, 12.1) (n = 101)	–6.4 (–13.8, 1.5) (n = 77)	–0.5 (–9.2, 9.0) (n = 75)	–5.8 (–14.5, 3.7) (n = 74)	0.8 (–7.9, 10.4) (n = 73)
Week 24 vs. Week 12	Percent change (95% CI)	7.8 (0.0, 16.2) (n = 101)	–0.4 (–10.9, 11.3) (n = 77)	–0.8 (–12.5, 12.4) (n = 74)	3.8 (–5.8, 14.5) (n = 76)	9.1 (–2.3, 21.7) (n = 73)
aPercent change = (geometric mean ratio – 1) × 100.